Dr. Amir Zarebkohan’s research focuses on the development of advanced nanomedicine strategies for targeted drug delivery and cancer therapy. His work integrates medical nanotechnology and physiology to design innovative nanosystems capable of precise drug transport within biological environments. He specializes in smart targeted delivery platforms, nano–bio interface studies, and nano chemo-immunotherapy approaches aimed at improving therapeutic efficacy while minimizing systemic toxicity. His current projects involve the co-delivery of cyclophosphamide and HLH peptide using D8 and RIVAP-modified chitosan nanoparticles, engineered to respond to the redox conditions of the tumor microenvironment for glioma targeting in rat models. Additionally, he is developing chitosan-based nanoparticles containing dendrimers loaded with cyclophosphamide and sitagliptin, further functionalized with targeting ligands for enhanced delivery efficiency. His research emphasizes translational applications of nanotechnology in oncology and the exploration of biocompatible polymeric carriers for controlled and localized drug release. Through his studies, Dr. Zarebkohan contributes to advancing nano-chemoimmunotherapeutic platforms that bridge the gap between nanoscience and clinical medicine, offering potential breakthroughs in the treatment of complex and resistant cancers.
Featured Publications:
Zarebkohan, A., & colleagues. (2024). Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model. Scientific Reports, 14, Article 75042.
Zarebkohan, A., & colleagues. (2024). Discovery of a novel dual targeting peptide for human glioma: From in-silico simulation to acting as targeting ligand. Advanced Pharmaceutical Bulletin, 14, Article 033.
Zarebkohan, A., & colleagues. (2023). Dual targeting salinomycin-loaded smart nano-micelles for enhanced accumulation and therapeutic outcome in breast cancer. International Journal of Pharmaceutics, 123095.
Zarebkohan, A., & colleagues. (2023). CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice. International Journal of Pharmaceutics, 122815.
Zarebkohan, A., & colleagues. (2023). Exosomal transmission of viruses, a two-edged biological sword. Cell Communication and Signalling, 21, Article 37.